DrugPatentWatch Database Preview
Drugs in Development Information for Dasotraline
Drug Development Status for Dasotraline: Patents, clinical trial progress, indications
Dasotraline is an investigational drug.
There have been 12 clinical trials for Dasotraline.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 31st 2017.
The most common disease conditions in clinical trials are Attention Deficit Disorder with Hyperactivity, Hyperkinesis, and Disease. The leading clinical trial sponsors are Sunovion and [disabled in preview].
There are nineteen US patents protecting this investigational drug and ninety international patents.
Summary for Dasotraline
| US Patents | 19 |
| International Patents | 90 |
| US Patent Applications | 32 |
| WIPO Patent Applications | 7 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2017-03-31) |
| Vendors | 10 |
Recent Clinical Trials for Dasotraline
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. | Sunovion | Phase 3 |
| A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder | Sunovion | Phase 3 |
| Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction | Sunovion | Phase 1 |
Clinical Trial Summary for Dasotraline
Top disease conditions for Dasotraline
Top clinical trial sponsors for Dasotraline
US Patents for Dasotraline
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Dasotraline | Start Trial | Preparation of chiral amides and amines | SUNOVION PHARMACEUTICALS INC. (Marlborough, MA) | Start Trial |
| Dasotraline | Start Trial | Dosage of dasotraline and method for treatment of ADHD | SUNOVION PHARMACEUTICALS INC. (Marlborough, MA) | Start Trial |
| Dasotraline | Start Trial | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine | SUNOVION PHARMACEUTICALS INC. (Marlborough, MA) | Start Trial |
| Dasotraline | Start Trial | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide | Sepracor Inc. (Marlborough, MA) | Start Trial |
| Dasotraline | Start Trial | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide | Sepracor Inc. (Marlborough, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Dasotraline
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Dasotraline | Australia | 2007233041 | 2026-03-31 | Start Trial |
| Dasotraline | Canada | 2648121 | 2026-03-31 | Start Trial |
| Dasotraline | China | 101421228 | 2026-03-31 | Start Trial |
| Dasotraline | China | 103588659 | 2026-03-31 | Start Trial |
| Dasotraline | Denmark | 2013835 | 2026-03-31 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
